Ignite Creation Date:
2025-12-24 @ 7:25 PM
Ignite Modification Date:
2026-03-05 @ 9:23 PM
Study NCT ID:
NCT03708003
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-04-27
First Post:
2018-10-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Sponsor:
Swiss Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SAKK 34/17
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None